Product Details:
| Dose/Strength | 90 mg |
| Packaging Size | 1*10 Tablets |
Brilinta 90mg is an antiplatelet medication containing ticagrelor that is prescribed to high-risk patients to prevent blood clots, heart attacks, and strokes. It works by preventing platelets from clumping together, and it is often used after an acute coronary syndrome or a heart attack, sometimes alongside a low dose of aspirin. Common side effects can include bleeding and shortness of breath (dyspnea).
How it works
Antiplatelet action:
Brilinta prevents platelets in the blood from sticking together, which reduces the formation of harmful blood clots.
Cardiovascular protection:
This helps lower the risk of serious cardiovascular events like heart attack and stroke in patients with certain heart conditions, including those who have received a stent.
Common side effects
Bleeding: The most common side effect is bleeding, which can take longer than usual to stop after an injury. Mild bleeding usually resolves on its own, but you should inform your doctor if it is persistent.
Shortness of breath (dyspnea): Some people may experience breathlessness. This often improves with continued treatment, but you should consult your doctor if it worsens or doesn't go away.
Other side effects: Other side effects may include dizziness and diarrhea.
Important considerations
Medical supervision:
You should only take Brilinta 90mg as prescribed by your doctor and should not stop taking it without consulting them.
Drug interactions:
Inform your doctor about all other medications you are taking to avoid potential interactions.
Contraindications:
Do not take Brilinta if you are allergic to ticagrelor or have active bleeding.
Pregnancy and breastfeeding:
Consult your doctor before taking this medication if you are pregnant or breastfeeding, as it may be unsafe.
Liver and kidney issues:
Use with caution if you have severe liver or kidney problems.
Lifestyle:
Maintain a healthy diet, exercise regularly, and avoid grapefruit and high-fat meals, as your doctor advises.